Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 clinical trial examining the safety, pharmacokinetics and pharmacodynamics
of escalating doses of the vascular disrupting agent NPI-2358 in patients with refractory
solid tumors or lymphoma. The formation of new blood vessels (angiogenesis) is an important
component of tumor growth and vascular disrupting agents are intended to target the
differences between these tumor blood vessels and the blood vessels in normal tissues.
NPI-2358 has also been seen to directly affect tumor cells.